Skip to main content

Advertisement

Table 6 Meta-analysis of association between clinicopathological parameters and HER3, Akt, p-Akt, mTOR, p-mTOR expression in gastric cancer

From: Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients

Target proteins Parameters Number of studies Number of patients Heterogeneity Model OR(95%CI) P value
I 2 (%) P value
HER3 Sex (male/female) 5 1034 18 0.30 FE 0.89(0.66,1.20) 0.44
Depth of invasion (T3 + T4/T1 + T2) 4 900 34 0.20 FE 2.39(1.62,3.54) <0.001
LN metastasis(positive/negative) 5 1034 68 0.02 RE 2.35(1.34,4.11) 0.003
Metastasis (positive/negative) 5 1034 47 0.10 FE 1.39(0.66,2.91) 0.39
Tumor stage (III + IV/I + II) 4 801 54 0.09 RE 1.38(0.76,2.49) 0.29
Akt Sex (male/female) 3 501 0 0.67 FE 0.99(0.66,1.49) 0.96
Age (>60/<60) 2 190 89 0 RE 1.24(0.17,8.88) 0.83
Tumor location (upper/low) 2 431 71 0.05 RE 0.69(0.26,1.79) 0.44
Differentiation (poor/well) 2 190 77 0.04 RE 1.63(0.35,7.53) 0.53
Depth of invasion (T3 + T4/T1 + T2) 1 120 1.18(0.45,3.10) 0.74
LN metastasis(positive/negative) 3 501 68 0.05 RE 1.27(0.44,3.61) 0.66
Metastasis (positive/negative) 3 501 72 0.03 RE 1.04(0.24,4.46) 0.96
Tumor stage (III + IV/I + II) 3 501 70 0.04 RE 1.17(0.45,3.00) 0.75
p-Akt Sex (male/female) 9 1477 0 0.79 FE 1.29(1.03,1.63) 0.03
Age (>60/<60) 5 1326 0 0.79 FE 0.95(0.74,1.20) 0.65
Tumor location (upper/low) 4 895 0 0.70 FE 1.03(0.78,1.37) 0.81
Differentiation (poor/well) 7 996 65 0.01 RE 1.14(0.65,2.02) 0.64
Depth of invasion (T3 + T4/T1 + T2) 7 1283 60 0.02 RE 1.23(0.80,1.90) 0.35
LN metastasis(positive/negative) 12 2019 69 0.00 RE 1.29(0.88,1.89) 0.19
Metastasis (positive/negative) 5 1351 66 0.02 RE 0.75(0.29,1.89) 0.54
Tumor stage (III + IV/I + II) 11 1597 62 0.003 RE 1.20(0.81,1.79) 0.36
mTOR Sex (male/female) 4 1637 0 0.95 FE 1.16(0.94,1.43) 0.17
Age (>60/<60) 2 1192 88 0.004 RE 1.90(0.59,6.06) 0.28
Tumor location (upper/low) 2 1148 0 0.87 FE 1.30(1.03,1.64) 0.03
Differentiation (poor/well) 3 1225 88 0 RE 1.59(0.33,7.57) 0.56
Depth of invasion (T3 + T4/T1 + T2) 3 1604 57 0.10 RE 0.88(0.59,1.31) 0.54
LN metastasis(positive/negative) 4 1637 74 0.01 RE 1.72(0.98,3.01) 0.06
Tumor stage (III + IV/I + II) 3 1225 89 0 RE 3.13(0.72,13.61) 0.13
p-mTOR Sex (male/female) 8 2994 0 0.60 FE 1.09(0.93,1.28) 0.30
Age (>60/<60) 5 2469 0 0.44 FE 1.46(1.24,1.72) <0.001
Tumor location (upper/low) 5 2001 11 0.35 FE 1.26(1.03,1.55) 0.03
Differentiation (poor/well) 4 1663 75 0.01 RE 0.99(0.57,1.72) 0.87
Depth of invasion (T3 + T4/T1 + T2) 4 1751 54 0.06 RE 1.63(1.08,2.45) 0.02
LN metastasis(positive/negative) 7 2294 90 0 RE 1.57(0.83,2.98) 0.17
Metastasis (positive/negative) 2 246 58 0.12 RE 1.05(0.25,4.44) 0.94
Tumor stage (III + IV/I + II) 6 2595 58 0.04 RE 1.73(1.29,2.32) <0.001
  1. OR odds ratio, CI confidence interval, FE fixed-effect model, RE random-effect model, LN metastasis: lymph node metastasis